Acute viral nasopharyngitis cost-effectiveness of therapy: Difference between revisions
Jump to navigation
Jump to search
Category |
m Bot: Removing from Primary care |
||
| Line 13: | Line 13: | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Needs overview]] | [[Category:Needs overview]] | ||
| Line 18: | Line 19: | ||
[[Category:Viral diseases]] | [[Category:Viral diseases]] | ||
[[Category:Inflammations|Nasopharyngitis]] | [[Category:Inflammations|Nasopharyngitis]] | ||
[[Category:Pulmonology]] | [[Category:Pulmonology]] | ||
[[Category:Otolaryngology]] | |||
[[Category:Pediatrics]] | [[Category:Pediatrics]] | ||
[[Category:Up-To-Date]] | [[Category:Up-To-Date]] | ||
[[Category:Infectious disease]] | [[Category:Infectious disease]] | ||
Latest revision as of 20:17, 29 July 2020
|
Acute viral nasopharyngitis Microchapters |
|
Differentiating acute viral nasopharyngitis from other diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Acute viral nasopharyngitis cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Acute viral nasopharyngitis cost-effectiveness of therapy |
|
FDA on Acute viral nasopharyngitis cost-effectiveness of therapy |
|
CDC on Acute viral nasopharyngitis cost-effectiveness of therapy |
|
Acute viral nasopharyngitis cost-effectiveness of therapy in the news |
|
Blogs onAcute viral nasopharyngitis cost-effectiveness of therapy |
|
Risk calculators and risk factors for Acute viral nasopharyngitis cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Cost Effectiveness of Therapy
- In the USA alone, the common cold leads to 75-100 million physician visits annually, at a conservative cost estimate of $7.7 billion per year.
- Americans spend $2.9 billion on over-the-counter drugs and another $400 million on prescribed medicines, both for symptomatic relief.
- More than one-third of patients who saw a doctor received an antibiotic prescription, not only contributes to unnecessary costs ($1.1 billion annually on an estimated 41 million antibiotic prescriptions in the United States), but also has implications for antibiotic resistance.
- An estimated 22-189 million school days are missed annually due to a cold. As a result, parents missed 126 million workdays to stay home to care for their children. When added to the 150 million workdays missed by employees suffering from a cold, the total economic impact of cold-related work loss exceeds $20 billion.[1]
References
- ↑ Fendrick, A. Mark; Monto, Arnold S.; Nightengale, Brian; Sarnes, Matthew (2003). "The Economic Burden of Non–Influenza-Related Viral Respiratory Tract Infection in the United States". Archives of Internal Medicine. 163 (4): 487. doi:10.1001/archinte.163.4.487. ISSN 0003-9926.